Beam Therapeutics Inc (BEAM): Rasio rega marang prakiraan pendapatan
Beam Therapeutics Inc. (BEAM) develops independently of macroeconomic cycles, relying on long-term achievements in gene editing. The change in the forward P/S ratio demonstrates the market valuation of future revenues, where 16.10 determines this parameter level. The company minimizes scientific risks by creating therapy methods for liver and blood pathologies. Project diversification in oncology and immunology further protects the business from potential failures in clinical trials.
Rincian analitis perusahaan Beam Therapeutics Inc. (BEAM)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- indikator beban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Beam Therapeutics Inc.|BEAM - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Beam Therapeutics Inc|BEAM - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku Beam Therapeutics Inc|BEAM - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Beam Therapeutics|Indikator likuiditas cepet beamtx.com
- rincian asil keuangan lan kelipatan valuasi:
BEAM - Bathi pungkasan|Proyeksi bathi mangsa ngarep Beam Therapeutics Inc.|BEAM - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Beam Therapeutics|BEAM - Rasio P/E diaturake wutah|Pangali EV/EBITDA Beam Therapeutics Inc|BEAM - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Beam Therapeutics|BEAM - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan beamtx.com|BEAM - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Beam Therapeutics Inc.
- rincian pendapatan lan dodolan:
Analisis komprehensif perusahaan:Beam Tx BEAM
The forward P/S ratio measures the premium investors are willing to pay per unit of future sales, enabling the timely identification of an overvalued asset to protect capital. Analyzing the P/S expectations for Beam Therapeutics Inc. (BEAM) reveals that the current valuation of Beam Therapeutics Inc. (BEAM) already prices in existing liquidity and R&D costs, while the results of DNA editing clinical trials remain uncertain.
Pesaing Beam Therapeutics Inc. (BEAM)
Multiplikator Forward P/S TEM (Tempus Labs)|Qiagen N.V. - Rasio rega marang prakiraan pendapatan|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep repligen.com|RNA: Multiplikator Forward P/S|CRISPR Therapeutics Inc (CRSP) - Multiplikator Forward P/S|WGS (GeneDx Holdings) - Multiplikator Forward P/S|RARE: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Kapitalisasi marang prakiraan pendapatan|10x Genomics Inc - Multiplikator forward rega marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rega mangsa ngarep marang pendapatan|Stoke Corp - Multiplikator Forward P/S|BLFS (BioLife) - Kapitalisasi marang prakiraan pendapatan|wavelifesciences.com (WVE) - Rasio rega marang prakiraan pendapatan|MAZE - Rasio kapitalisasi marang dodolan sing dikarepake|SION (Sionna Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Prime Medicine Corp (PRME)|Multiplikator Forward P/S TSHA|Multiplikator Forward P/S uniQure N.V. (QURE)|Rasio rega marang prakiraan pendapatan MeiraGTx Holdings plc MGTX|RGNX: Kapitalisasi marang prakiraan pendapatan|Solid Biosciences Inc - Multiplikator Forward P/S|OCGN - Multiplikator Forward P/S|PACB: Multiplikator Forward P/S|BNTC - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Design Therapeutics, Inc.|RCKT: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Korro Bio, Inc. KRRO|EDIT: Kapitalisasi marang prakiraan pendapatan|SLN - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Multiplikator forward rega marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Nautilus Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Metagenomi Therapeutics MGX|Rasio rega marang prakiraan pendapatan Precision BioSciences (DTIL)|GBIO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S BOLD (Boundless Bio, Inc)|XCUR - Multiplikator forward rega marang pendapatan|IMNN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals Corp|MBIO: Multiplikator Forward P/S|TransCode (RNAZ) - Multiplikator Forward P/S|BNGO (Bionano) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Applied DNA Sciences, Inc. APDN|Multiplikator Forward P/S BLUE|ImmunoPrecise Antibodies Ltd - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega Therapeutics OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON)|Rasio rega marang prakiraan pendapatan Unity Biotechnology, Inc.
